Anmelden Kostenlos registrieren

Cellectis EPS Q / Q

Was ist das EPS Q / Q von Cellectis?

EPS Q / Q von Cellectis ist -52.27%

Was ist die Definition von EPS Q / Q?



Die vierteljährliche EPS-Wachstumsrate, Quartal für Quartal , ist die Steigerung des EPS eines Unternehmens in den letzten vier Quartalen im Vergleich zu den Ergebnissen der vorangegangenen vier Quartale.

The earnings per share growth rate is an important factor for judging a company's value. EPS growth rate gives a good picture of the rate at which the company has grown its profitability in respect to the total number of shares. Comparing EPS history with stock price history helps determine the most likely future direction of the stock price.

Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.

EPS Q / Q von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Cellectis

Was macht Cellectis?

cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.

Unternehmen mit eps q / q ähnlich Cellectis